Bio-Rad Laboratories, Inc. BIOB
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 656.40M | 651.00M | 592.10M | 693.20M | 653.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 656.40M | 651.00M | 592.10M | 693.20M | 653.00M |
| Cost of Revenue | 303.10M | 305.20M | 282.70M | 348.40M | 310.20M |
| Gross Profit | 353.30M | 345.80M | 309.40M | 344.80M | 342.80M |
| SG&A Expenses | 215.40M | 211.80M | 212.10M | 217.30M | 204.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 578.80M | 578.20M | 557.70M | 631.70M | 585.00M |
| Operating Income | 77.60M | 72.80M | 34.40M | 61.50M | 68.00M |
| Income Before Tax | 538.70M | 542.10M | -689.80M | 929.20M | -431.10M |
| Income Tax Expenses | 80.10M | 170.70M | -162.70M | 209.20M | -89.20M |
| Earnings from Continuing Operations | 458.60M | 371.40M | -527.10M | 720.00M | -341.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 458.60M | 371.40M | -527.10M | 720.00M | -341.90M |
| EBIT | 77.60M | 72.80M | 34.40M | 61.50M | 68.00M |
| EBITDA | 118.80M | 113.90M | 75.30M | 104.00M | 112.20M |
| EPS Basic | 17.12 | 13.89 | -19.55 | 26.69 | -12.70 |
| Normalized Basic EPS | 1.81 | 1.96 | 1.06 | 1.90 | 1.66 |
| EPS Diluted | 17.02 | 13.85 | -19.55 | 26.65 | -12.70 |
| Normalized Diluted EPS | 1.80 | 1.95 | 1.06 | 1.90 | 1.66 |
| Average Basic Shares Outstanding | 26.78M | 26.75M | 26.96M | 26.98M | 26.92M |
| Average Diluted Shares Outstanding | 26.95M | 26.81M | 26.96M | 27.01M | 26.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |